Treat ER+ight: Treatment of Canadian postmenopausal women with ER+ HER2- advanced breast cancer in the real-world setting with hormone therapy ± targeted therapy.

Background: Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of median duration of treatment and the overall response rate in a real-world setting. Methods: For the purpose of the present analysis, we considered two data sets of HR+ ABC patients collected in Italy between 2012 and 2015 (EVA and GIM-13 AMBRA studies). Results: Eighty-one and 91 patients have been identified from the two data sets. The median age was 63 years (range 35–82) for the EVA and 57.8 years (range 35.0–82.3) for the AMBRA patients. ORRs were 23.5 and 24.3% in the whole population, 26.9% in the patients with bone only, and 21.8 and 21.4% in those with visceral metastases. The median duration of HD-FUL was 11.6 months (range 1–48) and 12.4 months (range 2.9–70.0) in the two data sets, respectively. Conclusion: These data suggest that HD-FUL should still continue to play a significant role as first-line therapy in HR+ ABC patients.

Download Full-text

Eribulin for advanced breast cancer: Clinical experience in the real world.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.e12003 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e12003-e12003

Author(s):

Richard C. Walshaw ◽

Shazril Shaukat ◽

Kevin Chan ◽

Anne Caroline Armstrong ◽

Sacha Jon Howell ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Clinical Experience ◽

Real World ◽

Advanced Breast ◽

The Real

Download Full-text

Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer

Advances in Therapy ◽

10.1007/s12325-017-0644-2 ◽

2017 ◽

Vol 34 (12) ◽

pp. 2566-2584 ◽

Cited By ~ 2

Author(s):

Zhou Zhou ◽

Derek H. Tang ◽

Jipan Xie ◽

Rajeev Ayyagari ◽

Eric Wu ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Targeted Therapy ◽

Literature Review ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Systematic Literature Review ◽

Advanced Breast ◽

The Impact

Download Full-text

CDK4/6 inhibitors and hormone therapy in hormone receptor-positive advanced breast cancer: Real-world data and intrinsic subtypes defined by PAM50.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.15_suppl.e13035 ◽

2020 ◽

Vol 38 (15_suppl) ◽

pp. e13035-e13035

Author(s):

Tamara Diaz Redondo ◽

Rocío Lavado-Valenzuela ◽

Maria Emilia Dominguez-Recio ◽

Sofía Ruíz ◽

Encarnación González Flores ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trials ◽

Advanced Breast Cancer ◽

Hormone Therapy ◽

Real World ◽

Hormone Receptor ◽

Advanced Breast ◽

Real World Data ◽

World Data ◽

Hormone Receptor Positive

e13035 Background: CDK 4/6 inhibitors plus hormone therapy(HT) has been approved by FDA and EMA for the treatment of hormone receptor positive HER2 negative advanced breast cancer (HR+/HER2-BC) with improvement in PFS consistently demonstrated in several clinical trials. Benefit in OS has also been demonstrated in Monaleesa3 and Monarch2 clinical trials. To date we don`t have real-world data and no single biomarker has been validated to identify subgroups that would benefit most from this new drugs. Methods: This is a multicenter, real life, observational study. From January 2015 to December 2019 we recruited 98 patients with immunohistochemical(IHC) HR+/HER2-BC treated with CDK4-6 inhibitor plus HT. All patients were classified into intrinsic molecular subtypes based on PAM50 signature done centrally in diagnostic/metastatic biopsies. Results: The clinical and treatment characteristic are in table. In IHC studies all population were classified as luminalA (40%) and LuminalB (60%) but we found HER2 enriched patients (6%) defined by PAM50. The median PFS for all population was 14 months and median PFS for Luminal A subtype was 12 months and 15 months for Luminal B with no statistically significant differences between them. Conclusions: Based on the results obtained, the intrinsic molecular subtype defined by PAM50 does not appear to be associated with differences in PFS in our study group. However, a study with a larger number of patients would be necessary. Inhibitors of CDK4/6, have established a central role in the management of HR+/HER2-BC. There is a clear benefit in PFS and OS but we still don’t know which patients will benefit from this therapy and who will not while the side effects such chronic neutropenia, QTC prolongation and diarrhea could have a negative impact on their quality of life. Its mandatory to explore a good biomarker to direct therapy. [Table: see text]

Download Full-text